Arcus Biosciences (NYSE:RCUS) CFO Sells $132,073.60 in Stock

Arcus Biosciences, Inc. (NYSE:RCUS) CFO Robert Goeltz II sold 5,960 shares of the stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $22.16, for a total transaction of $132,073.60. Following the sale, the chief financial officer owned 74,476 shares of the company’s stock, valued at $1,650,388.16. This trade represents a 7.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Arcus Biosciences Stock Performance

RCUS stock traded down $0.26 during trading on Thursday, hitting $22.02. The company had a trading volume of 1,175,874 shares, compared to its average volume of 1,200,446. The firm has a 50-day moving average price of $20.82 and a 200-day moving average price of $13.98. The company has a quick ratio of 3.65, a current ratio of 3.65 and a debt-to-equity ratio of 0.22. The firm has a market cap of $2.38 billion, a PE ratio of -6.40 and a beta of 0.75. Arcus Biosciences, Inc. has a 1-year low of $6.50 and a 1-year high of $26.40.

Arcus Biosciences (NYSE:RCUS) last announced its earnings results on Tuesday, October 28th. The company reported ($1.27) earnings per share for the quarter, beating the consensus estimate of ($1.33) by $0.06. The company had revenue of $26.00 million for the quarter, compared to the consensus estimate of $19.89 million. Arcus Biosciences had a negative return on equity of 68.17% and a negative net margin of 136.40%.The company’s revenue was down 45.8% on a year-over-year basis. During the same period last year, the business posted ($1.00) EPS. On average, analysts expect that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current year.

Institutional Trading of Arcus Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its position in shares of Arcus Biosciences by 24.1% in the first quarter. Vanguard Group Inc. now owns 6,687,800 shares of the company’s stock valued at $52,499,000 after purchasing an additional 1,298,584 shares during the period. Charles Schwab Investment Management Inc. lifted its position in Arcus Biosciences by 23.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 714,002 shares of the company’s stock worth $5,605,000 after buying an additional 134,379 shares during the period. Maryland State Retirement & Pension System boosted its stake in Arcus Biosciences by 10.9% in the 1st quarter. Maryland State Retirement & Pension System now owns 20,202 shares of the company’s stock worth $159,000 after buying an additional 1,986 shares during the last quarter. Swiss National Bank grew its holdings in Arcus Biosciences by 35.9% in the 1st quarter. Swiss National Bank now owns 133,596 shares of the company’s stock valued at $1,049,000 after buying an additional 35,300 shares during the period. Finally, Invesco Ltd. increased its stake in shares of Arcus Biosciences by 24.5% during the 1st quarter. Invesco Ltd. now owns 254,024 shares of the company’s stock valued at $1,994,000 after acquiring an additional 50,037 shares during the last quarter. 92.89% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

RCUS has been the topic of a number of research analyst reports. HC Wainwright boosted their price objective on shares of Arcus Biosciences from $28.00 to $32.00 and gave the stock a “buy” rating in a report on Friday, December 12th. Bank of America boosted their price target on Arcus Biosciences from $17.00 to $26.00 and gave the stock a “neutral” rating in a research note on Friday, November 28th. Wedbush set a $35.00 price target on Arcus Biosciences and gave the stock an “outperform” rating in a report on Wednesday, October 29th. UBS Group reaffirmed a “buy” rating on shares of Arcus Biosciences in a research note on Monday. Finally, Wall Street Zen upgraded Arcus Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday. Eight investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $28.89.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.